Completed PHASE2 INTERVENTIONAL NCT00005055

Glufosfamide With of Without Hydration in Treating Patients With Advanced Non-small Cell Lung Cancer

Open Label Phase II Study on Glufosfamide Administered as a 60 Minute Infusion Every 3 Weeks in Advanced Non Small Cell Lung Cancer

Sponsor: European Organisation for Research and Treatment of Cancer - EORTC

Conditions Lung Cancer

Interventions glufosfamide

Updated 5 times since 2017 Last updated: Sep 20, 2012 Started: Jan 31, 2000 Primary completion: Mar 31, 2001

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Lung Cancer and is currently completed. European Organisation for Research and Treatment of Cancer - EORTC leads this study, which shows 5 recorded versions since 2000 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2000

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

European Organisation for Research and Treatment of Cancer - EORTC

Data source: European Organisation for Research and Treatment of Cancer - EORTC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Nantes-Saint Herblain, France